Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht(Hospital for Sick Children), Larry A. Greenbaum(Emory University), Petra Muus(Radboud University Medical Center), Sunil Babu(Fort Wayne Medical Institute), Camille L. Bedrosian(Alexion Pharmaceuticals (United States)), David J. Cohen(Columbia University Irving Medical Center), Yahsou Delmas(Centre Hospitalier Universitaire de Bordeaux), Kenneth Douglas(Beatson West of Scotland Cancer Centre), Richard R. Furman(Cornell University), Osama Gaber(Methodist Hospital), Timothy H.J. Goodship(Newcastle University), Maria Herthelius(Karolinska University Hospital), Maryvonne Hourmant(Centre d'Investigation Clinique de Nantes), Christophe Legendre(Université Paris Cité), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Neil Sheerin(Newcastle University), Antonella Trivelli(Istituto Giannina Gaslini), Chantal Loirat(Hôpital Robert-Debré)
Kidney International
February 4, 2015
Cited by 414Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis